- ICF ( NASDAQ: ICFI ) has been selected as one of the five awardees for a new IDIQ contract to provide epidemiologic and clinical operations support for studies and other research activities.
- The IDIQ contract has a ceiling value of $320M across all awardees and 10-year term, including a five-year base and a five-year option period.
- ICF ( ICFI ) will provide field preparation and study management, exposure assessment and clinical support to the National Cancer Institute's Division of Cancer Epidemiology and Genetics. This will include simultaneously managing concurrent multidisciplinary domestic and international epidemiologic and genetic studies of varying sizes and complexity.
For further details see:
ICF selected for epidemiology and genetics research IDIQ